AstraZeneca Annual Report and Form 20-F Information 2008

Science committee

Science Committee members have a knowledge of, or an interest in, life sciences. During 2008, its members were Nancy Rothwell (Science Committee Chairman), Jane Henney, Jan Lundberg, John Patterson and Bo Angelin. They are all Non-Executive Directors, except Jan Lundberg and John Patterson. The Global Head Discovery, Strategy and Performance, also attends all meetings and acts as secretary to this Committee.

The Science Committee’s principal tasks are:

• To provide assurance to the Board regarding the quality, integrity and competitiveness of the Company’s science-based R&D activities. The Committee aims to assure itself that the approaches and targets adopted throughout the R&D organisation are competitive and an appropriate use of shareholders’ funds, but is not expected to review individual research or licensing projects.
• To consider reports from or join any meeting with any relevant external advisory board when the Company is considering entry into new areas of science or medicine.
• To review, from time to time, together with other external experts important bioethical issues faced by the Company and to assist in the formulation of, and to agree on behalf of the Board, appropriate policies in relation to such issues.
• To consider with external experts, from time to time, future trends in medical science and technology.

The Science Committee’s remit is available on the Company’s website, astrazeneca.com.

The Science Committee met twice in 2008 to review and discuss its remit and method of operation, the Company’s Cardiovascular and Neuroscience R&D, innovation with R&D, emerging areas of science and its science policy. Each member participated in both meetings.

Back to the top